Kelly John Alexander 4

Accession 0001628280-26-003147

CIK 0001357874other

Filed

Jan 21, 7:00 PM ET

Accepted

Jan 22, 6:48 PM ET

Size

16.4 KB

Accession

0001628280-26-003147

AI-generated summary of this filing

Updated Jan 22, 2026

Precision Biosciences (DTIL) CFO Kelly Alexander Receives RSUs, Sells 15,213

What Happened

Kelly John Alexander, Chief Financial Officer of Precision Biosciences (DTIL), had Restricted Stock Units (RSUs) vest on Jan 20, 2026 that converted into 44,363 shares (3,888 + 13,900 + 26,575). Under a pre-existing Rule 10b5-1 plan, he sold 15,213 of those shares on Jan 21, 2026 at $4.03 per share, generating $61,308. The remaining vested shares (approximately 29,150) were retained by the reporting person after the sell-to-cover tax withholding.

Key Details

Transaction dates: RSU vesting/conversion on 2026-01-20; open-market sale on 2026-01-21.
Sale details: 15,213 shares sold at $4.03 each, proceeds $61,308; sale executed pursuant to a 10b5-1 plan (sell-to-cover for taxes).
RSU issuance: 44,363 shares issued from vesting (3,888; 13,900; 26,575).
Post-transaction: ~29,150 vested shares remained issued to the insider from this vesting event (44,363 vested minus 15,213 sold), based on this filing.
Footnotes of note: sales were strictly sell-to-cover for tax/withholding obligations under a 10b5-1 trading plan adopted Jan 17, 2025; RSUs represent contingent rights to one share each; RSU grants originated on 1/20/2023, 4/18/2024, and 8/22/2024 with multi-year vesting schedules.
Filing timeliness: Reported on 2026-01-22 for a 2026-01-20 vesting — filed within the normal Form 4 reporting window (timely).

Context

This was RSU vesting and a routine sell-to-cover tax withholding, not a discretionary open-market sell for investment purposes. The derivative entries reflect conversion/settlement of RSUs into common shares (not an options-for-cash purchase). Such sell-to-cover transactions are common following equity awards and do not by themselves imply a change in insider market sentiment.

Form 4

Period: 2026-01-20

Chief Financial Officer

Transactions

Exercise/Conversion
Common Stock
[F1][F2]
2026-01-20+3,888→ 81,186 total
Exercise/Conversion
Common Stock
[F1][F2]
2026-01-20+13,900→ 95,086 total
Exercise/Conversion
Common Stock
[F1][F2]
2026-01-20+26,575→ 121,661 total
Sale
Common Stock
[F3]
2026-01-21$4.03/sh−15,213$61,308→ 106,448 total
Exercise/Conversion
Restricted Stock Units
[F2][F4]
2026-01-20−3,888→ 0 total
→ Common Stock (3,888 underlying)
Exercise/Conversion
Restricted Stock Units
[F2][F5]
2026-01-20−13,900→ 13,901 total
→ Common Stock (13,900 underlying)
Exercise/Conversion
Restricted Stock Units
[F2][F6]
2026-01-20−26,575→ 26,575 total
→ Common Stock (26,575 underlying)

Footnotes (6)

[F1]Represents the vesting of Restricted Stock Units ("RSUs") on January 20, 2026.
[F2]Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
[F3]The sales were effected pursuant to a Rule 10b5-1 plan adopted on January 17, 2025. The transaction was a sell-to-cover, with shares only sold to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The Reporting Person did not sell or otherwise dispose of shares reported on this Form 4 for any reason other than to cover required taxes and fees.
[F4]On January 20, 2023 the Reporting Person was granted RSUs, which vested in three substantially equal annual installments beginning on January 20, 2024, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.
[F5]On April 18, 2024 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on January 20, 2025, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.
[F6]On August 22, 2024 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on January 20, 2025, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

Signature

/s/ Dario Scimeca, Attorney-in-fact for John Alexander Kelly|2026-01-22

1 file

PRECISION BIOSCIENCES INC

CIK 0001357874

Entity typeother